Answers are grounded in this paper and cite their sources.
Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disease characterized by microvascular injury, immune dysregulation, and progressive fibrosis affecting the skin and internal organs. The disease typically develops between 45 and 60 years of age, and patients with late-onset SSc often experience more aggressive disease progression and poorer clinical outcomes. Despite advances in disease management, effective therapies targeting the underlying pathogenic mechanisms remain limited. Emerging evidence suggests that metabolic alterations associated with aging, cellular senescence, and SSc may interact to influence fibroblast activation, endothelial dysfunction, immune-cell responses, and extracellular matrix remodeling. Alterations in glucose, lipid, amino acid, and mitochondrial metabolism have been reported in SSc and experimental models of fibrosis; however, their causal relationships with biological aging and disease progression vary in evidential strength. This review summarizes current evidence on metabolic remodeling in key cellular populations involved in SSc, discusses potential interactions among cellular senescence, metabolic regulation, and the fibrotic microenvironment, and evaluates emerging metabolism-targeted therapeutic strategies. Particular attention is given to distinguishing findings established in SSc from mechanisms inferred from aging research or other fibrotic diseases. A clearer understanding of these relationships may help identify disease-relevant metabolic pathways and guide future mechanistic and translational studies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: